Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
51.1M
-
Shares change
-
+1.24M
-
Total reported value, excl. options
-
$166M
-
Value change
-
+$3.04M
-
Put/Call ratio
-
3.98
-
Number of buys
-
37
-
Number of sells
-
-48
-
Price
-
$3.26
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q4 2021
105 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q4 2021.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.1M shares
.
Largest 10 shareholders include FMR LLC (9.06M shares), Bain Capital Life Sciences Investors, LLC (6.26M shares), BlackRock Inc. (4.23M shares), Ally Bridge Group (NY) LLC (3.54M shares), Artal Group S.A. (3M shares), Flagship Pioneering Inc. (2.94M shares), VANGUARD GROUP INC (2.79M shares), Omega Fund Management, LLC (2.51M shares), Samsara BioCapital, LLC (2.19M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1.9M shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.